Alexander V Vlassov
Overview
Explore the profile of Alexander V Vlassov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schageman J, Zeringer E, Li M, Barta T, Lea K, Gu J, et al.
Biomed Res Int
. 2013 Nov;
2013:253957.
PMID: 24205503
Exosomes are small (30-150 nm) vesicles containing unique RNA and protein cargo, secreted by all cell types in culture. They are also found in abundance in body fluids including blood,...
12.
Ramirez C, Rotllan N, Vlassov A, Davalos A, Li M, Goedeke L, et al.
Circ Res
. 2013 Mar;
112(12):1592-601.
PMID: 23519695
Rationale: Foam cell formation because of excessive accumulation of cholesterol by macrophages is a pathological hallmark of atherosclerosis, the major cause of morbidity and mortality in Western societies. Liver X...
13.
Hickerson R, Gonzalez-Gonzalez E, Vlassov A, Li M, Lara M, Contag C, et al.
Nucleic Acid Ther
. 2012 Oct;
22(6):438-43.
PMID: 23098239
Development of RNA interference (RNAi)-based therapeutics has been hampered by the lack of effective and efficient means of delivery. Reliable model systems for screening and optimizing delivery of RNAi-based agents...
14.
Guzman-Villanueva D, El-Sherbiny I, Herrera-Ruiz D, Vlassov A, Smyth H
J Pharm Sci
. 2012 Aug;
101(11):4046-66.
PMID: 22927140
RNA interference has emerged as a potentially powerful tool in the treatment of genetic and acquired diseases by delivering short interfering RNA (siRNA) or microRNA (miRNA) to target genes, resulting...
15.
Liu C, Kelnar K, Vlassov A, Brown D, Wang J, Tang D
Cancer Res
. 2012 Jun;
72(13):3393-404.
PMID: 22719071
MiRNAs regulate cancer cells, but their potential effects on cancer stem/progenitor cells are still being explored. In this study, we used quantitative real-time-PCR to define miRNA expression patterns in various...
16.
Vlassov A, Magdaleno S, Setterquist R, Conrad R
Biochim Biophys Acta
. 2012 Apr;
1820(7):940-8.
PMID: 22503788
Background: Cells continuously secrete a large number of microvesicles, macromolecular complexes, and small molecules into the extracellular space. Of the secreted microvesicles, the nanoparticles called exosomes are currently undergoing intense...
17.
Gao L, Gao Y, Li X, Howell P, Kumar R, Su X, et al.
Mol Oncol
. 2011 Dec;
6(1):81-7.
PMID: 22130551
The integral membrane channel protein aquaporin (AQP) is aberrantly expressed with oncogenic characteristics in various human cancers. In this study, we analyzed the expression pattern of all subtypes of AQPs,...
18.
Cheng A, Magdaleno S, Vlassov A
Methods Mol Biol
. 2011 Jul;
764:199-213.
PMID: 21748642
RNA interference (RNAi) is a mechanism by which the introduction of small interfering RNAs (siRNAs) into cultured cells causes degradation of the complementary mRNA. Applications of RNAi include gene function...
19.
Cheng A, Vlassov A, Magdaleno S
Methods Mol Biol
. 2011 Jul;
764:183-97.
PMID: 21748641
RNA interference (RNAi) is a regulatory mechanism of eukaryotic cells that uses small interfering RNAs (siRNA) to direct homology-dependent control of gene activity. Applications of RNAi include functional genomics, in...
20.
Ghosn B, Singh A, Li M, Vlassov A, Burnett C, Puri N, et al.
Oligonucleotides
. 2010 Jun;
20(3):163-72.
PMID: 20565242
Despite high specificity and potency, small interfering RNA (siRNA)-based therapeutics have been limited by their poor biostability and intracellular penetration. Thus, effective nanocarriers that can protect and efficiently deliver siRNA...